Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Enhanced tumor immune surveillance through neutrophil reprogramming due to Tollip deficiency
Yao Zhang, Christina Lee, Shuo Geng, Liwu Li
Yao Zhang, Christina Lee, Shuo Geng, Liwu Li
View: Text | PDF
Research Article Inflammation Oncology

Enhanced tumor immune surveillance through neutrophil reprogramming due to Tollip deficiency

  • Text
  • PDF
Abstract

Although the importance of the tumor immune environment for the modulation of tumorigenesis and tumor regression is becoming increasingly clear, most of the research related to tumor-immune therapies has focused on adaptive immune cells, while the role and regulation of innate leukocytes such as neutrophils remains controversial and less defined. Here we observed that the selective deletion of Tollip, a key innate immune-cell modulator, led to enhanced tumor immune surveillance in a chemically induced colorectal cancer model. Tollip-deficient neutrophils significantly elevated T cell activation through enhanced expression of the costimulatory molecule CD80, and reduced expression of the inhibitory molecule PD-L1. Mechanistically, Tollip deficiency increased STAT5 and reduced STAT1, the transcription factors responsible for the expression of CD80 and PD-L1, respectively. Through adoptive transfer, we demonstrate that Tollip-deficient neutrophils, but not Tollip-deficient monocytes, are sufficient to drive enhanced tumor immune surveillance and reduced colorectal cancer burden in vivo. Our data reveal a strategy for the reprogramming of neutrophil functions conducive for the enhancement of the antitumor immune environment.

Authors

Yao Zhang, Christina Lee, Shuo Geng, Liwu Li

×

Figure 6

Adoptive transfer of Tollip–/– neutrophils to WT mice slows down colitis-associated cancer progression.

Options: View larger image (or click on image) Download as PowerPoint
Adoptive transfer of Tollip–/– neutrophils to WT mice slows down colitis...
(A) Representative images of colons on day 64 from WT mice that received WT or Tollip–/– neutrophils. (B) Graphical representation of tumor burden in WT mice that received WT or Tollip–/– neutrophils. n ≥ 5 per group. (C) H&E-stained sections of colons from the mice that received WT or Tollip–/– neutrophils. Colons were collected in Swiss rolls at the end of the AOM-DSS regimen. Scale bars: 2.5 mm (top) and 0.5 mm (bottom). (D) Immunofluorescence analysis of Ki67 and β-catenin. Blue color is DAPI staining. Scale bars: 200 μm. (E) CD4+ and CD8+ cell counts in the spleens from the mice that received WT or Tollip–/– neutrophils. (F) Percentages of CD62Llo in CD8+ T cells. Percentage of granzyme B–positive (GrzB+) cells in CD8+ T cells. Statistical significance compared with WT in the same treatment conditions was determined by Student’s t test (B) or Mann-Whitney U test (E and F). *P < 0.05, **P < 0.01, ***P < 0.001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts